Optimization strategy for the early timing of bronchoalveolar lavage treatment for children with severe mycoplasma pneumoniae pneumonia

Table 2 Comparison of early and late TBAL group [n (%), M (IQR)]

Index	Early (n = 52)	Late (n = 192)	Z/χ2	P
Fever, d	7(3.25,12.75)	6(3,10)	0.169	0.866
Cough, d	7(3,12.75)	7(3,10)	0.419	0.675
Extrapulmonary complications, n (%)	28 (53.85)	95 (49.48)	0.312	0.576
Pleural effusion, n (%)	15 (28.85)	53 (27.60)	0.482	0.487
Hospitalization time, d	10(9,14)	13(10,17.75)	3.043	0.002
SMPP, n (%)	16 (30.77)	52 (27.08)	0.277	0.599
RMPP, n (%)	24 (46.15)	81 (42.19)	0.2626	0.608
APACHE II change	3(0,7)	3(0,8)	0.284	0.776
SOFA	2(0,3.75)	2(0,4)	0.061	0.951

* SMPP: Severe mycoplasma pneumoniae pneumonia, RMPP: Refractory mycoplasma pneumoniae pneumonia, APACHE: Acute Physiology and Chronic Health Evaluation, SOFA: Sequential organ failure assessment

ISSN: 1471-2334